Abstract
We clinicopathologically studied a total of 13 cases of breast neuroendocrine ductal carcinoma, including four cases of non-invasive and the remaining nine cases of invasive, treated at our hospital in the past five-year period from 2007 to 2012. A mean age of the patients was 67.6 years, ranging from 43 to 82. There was 12 women and one man. In all cases except one in which we could not obtain data, both ER and PgR were positive. HER2 was negative in all cases except one case of DCIS. Most patients were seen at our hospital after they noticed a breast mass, and some patients complained of abnormal nipple discharge. Tumorous lesions were revealed on MMG in most cases. On immunestaining, CD56 was positive in 12 out of 13 cases, synaptophysin was positive in all the 13 cases, and chromogranin A was positive in five out of seven cases. By conducting two kinds of immunostainings at least, we confirmed the differentiation toward neuroendocrine carcinoma. The Ki-67 level was elevated in three out of six cases. All the patients have been well without recurrence as of April 2013.
Neuroendocrine ductal carcinoma in situ of the breast is a relatively rare entity. We must further accumulate clinical cases to study the therapeutic methods and the prognosis of the disease.
